Phase 3 · NCT05882045
TRIUMPH-3
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
What this means
The sponsor announced these results. A linked, verified peer-reviewed results publication is not confirmed in the stored records.
Figure / record sourceLast verified 30 Sept 2026
Registry record
Trial details
- Trial
- TRIUMPH-3
- ClinicalTrials.gov ID
- NCT05882045
- Indication
- Obesity, Cardiovascular Diseases
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 1,946
- Status
- Completed
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 169 sites · Argentina, Australia, Canada, Hungary, Mexico, Poland, Puerto Rico, Slovakia, Spain, United States
- Study start
- 30 May 2023
- Primary completion
- 16 Apr 2026
- Study completion
- 14 May 2026
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 30 Jul 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Body Mass Index (BMI); Change from Baseline in Waist Circumference; Percent Change from Baseline in Total Cholesterol; Percent Change from Baseline in Triglycerides; Change from Baseline in Systolic Blood Pressure (SBP); Change from Baseline in Diastolic Blood Pressure (DBP); Change from Baseline in Hemoglobin A1c (HbA1c); Percent Change from Baseline in Fasting Insulin; Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score; Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)
Registry monitoring
Latest Trial Changes
| Field | Change | Detected | Source |
|---|---|---|---|
| Recruitment status | Recruiting→Completed | 4 Sept 2026 | ClinicalTrials.gov |
| Enrolment | 1200→1946 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary completion date | 2027-09-30→2026-04-16 | 4 Sept 2026 | ClinicalTrials.gov |
| Study completion date | Not yet confirmed→2026-05-14 | 4 Sept 2026 | ClinicalTrials.gov |
| Primary endpoints | Not yet confirmed→Percent Change from Baseline in Body Weight | 4 Sept 2026 | ClinicalTrials.gov |